The Minimal Residual Disease market report also offers comprehensive insights into the Minimal Residual Disease market size, share, Minimal Residual Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Minimal Residual Disease market size growth forward.
Some of the key highlights from the Minimal Residual Disease Market Insights Report:
In June 2023, NeoGenomics’ RaDaR assay, a personalized liquid biopsy for MRD detection, received its first pan-cancer commercial coverage by Blue Shield of California. Effective August 1, 2023, this coverage expands access to MRD testing across various cancer types, enhancing early detection and monitoring capabilities.
In 2021, the Minimal Residual Disease (MRD) market size across the seven major markets (7MM) was approximately $700 million.
Prominent MRD detection products include ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, TRUPCR® PML-RARA, Signatera, Leukemia Fusion Gene One-Step Detection Kits, CBFB/MYH11 inv(16), Seq-MRD, LymphoTrack, Idylla Technology, and others.
According to DelveInsight, the MRD market is projected to experience robust growth from 2023 to 2032, driven by the introduction of new therapies and an increasing number of diagnosed cases. Several leading pharmaceutical and biotechnology companies, including Adaptive Biotechnologies, Bristol-Myers Squibb, Natera, Kite Pharma, and Amgen Inc., are actively engaged in advancing the MRD market.
Strategise your business goals by understanding market dynamics @ Minimal Residual Disease Market Landscape
Minimal Residual Disease Overview
Minimal residual disease (MRD) refers to a small number of cancer cells that persist in the body following treatment. These remaining cells are often too few to cause noticeable symptoms and may go undetected by conventional methods, such as microscopic examination or monitoring abnormal serum proteins in the blood. An MRD-positive test indicates the presence of residual cancer cells, while an MRD-negative result suggests that no detectable disease remains.
Do you know the treatment paradigms for different countries? Download our Minimal Residual Disease Market Sample Report
Minimal Residual Disease Epidemiology Insights
According to the American Cancer Society’s 2022 statistics, there were an estimated 34,470 new cases of multiple myeloma in the United States that year. Additionally, approximately 6,660 new cases of acute lymphocytic leukemia (ALL) were reported in 2022.
Minimal Residual Disease Epidemiology Segmentation
DelveInsight’s Minimal Residual Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Minimal Residual Disease historical patient pools and forecasted Minimal Residual Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Minimal Residual Disease Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Minimal Residual Disease Prevalence
Age-Specific Minimal Residual Disease Prevalence
Gender-Specific Minimal Residual Disease Prevalence
Diagnosed and Treatable Cases of Minimal Residual Disease
Visit for more @ Minimal Residual Disease Epidemiological Insights
Minimal Residual Disease Market Outlook
The Minimal Residual Disease (MRD) market is poised for significant growth, driven by advancements in detection technologies, increasing cancer prevalence, and the growing adoption of MRD testing in clinical practice. MRD refers to the small number of cancer cells that remain in a patient’s body after treatment, often undetectable by traditional diagnostic methods but measurable using highly sensitive molecular and genomic techniques.
Minimal Residual Disease Market Size and Growth Trends
In 2021, the MRD market across the seven major markets (7MM) was valued at approximately $700 million. According to market forecasts, the sector is expected to experience substantial growth, fueled by:
The rising incidence of hematologic malignancies such as multiple myeloma, acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL).
Increased integration of MRD testing in treatment monitoring and clinical decision-making.
The expansion of personalized medicine and targeted therapies that rely on MRD detection for improved patient outcomes.
Key Technologies andMinimal Residual Disease market Market Drivers
Several innovative technologies are shaping the MRD market, including:
ClonoSEQ – A next-generation sequencing (NGS)-based MRD test.
PhasED-Seq – A highly sensitive sequencing platform for tracking residual cancer.
Signatera – A tumor-informed MRD assay used for personalized monitoring.
MRDx BCR-ABL Test – A molecular diagnostic tool for chronic myeloid leukemia (CML).
LymphoTrack & Idylla Technology – Advanced diagnostic solutions improving MRD detection accuracy.
The increasing regulatory approvals and adoption of liquid biopsy techniques are also contributing to the market’s expansion, offering a less invasive method for monitoring disease recurrence.
Leading Companies in the MRD Market
Several major pharmaceutical and biotech companies are actively developing and commercializing MRD solutions, including:
Adaptive Biotechnologies
Bristol-Myers Squibb Company
Natera
Kite Pharma
Amgen Inc.
These companies are focusing on research and development to enhance the sensitivity and specificity of MRD tests, as well as integrating artificial intelligence (AI) and bioinformatics for improved data analysis.
Minimal Residual Disease Future Outlook and Opportunities
The Minimal Residual Disease market is expected to witness rapid advancements, particularly in the field of immunotherapy and CAR-T cell therapies, where MRD testing plays a crucial role in treatment planning. Additionally, the expansion of MRD testing beyond hematologic malignancies to solid tumors, such as breast and colorectal cancer, presents a promising growth opportunity.
Overall, with the continued innovation, regulatory support, and increasing adoption of precision medicine, the MRD market is set to expand significantly in the coming years, transforming cancer diagnostics and treatment monitoring.
Minimal Residual Disease Marketed Therapies
Cinqair (reslizumab): Teva Pharmaceutical
Fasenra (benralizumab): AstraZeneca
Minimal Residual Disease Emerging Therapies
GSK3511294 (Depemokimab): GlaxoSmithKline
PT010: AstraZeneca
Minimal Residual Disease Key Companies
Adaptive Biotechnologies, Bristol-Myers Squibb Company, Natera, Kite Pharma, Amgen Inc., and others
For more information, visit Minimal Residual Disease Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Minimal Residual Disease Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Minimal Residual Disease, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Minimal Residual Disease epidemiology in the 7MM
Minimal Residual Disease marketed and emerging therapies
Minimal Residual Disease companies
Minimal Residual Disease market drivers and barriers
Table of Contents:
1 Minimal Residual Disease Market Key Comprehensive Insights
2 Minimal Residual Disease Market Report Introduction
3 Competitive Intelligence Analysis for Minimal Residual Disease
4 Minimal Residual Disease Market Analysis Overview at a Glance
5 Executive Summary of Minimal Residual Disease
6 Minimal Residual Disease Epidemiology and Market Methodology
7 Minimal Residual Disease Epidemiology and Patient Population
8 Minimal Residual Disease Patient Journey
9 Minimal Residual Disease Treatment Algorithm, Minimal Residual Disease Current Treatment, and Medical Practices
10 Key Endpoints in Minimal Residual Disease Clinical Trials
11 Minimal Residual Disease Marketed Therapies
12 Minimal Residual Disease Emerging Therapies
13 Minimal Residual Disease: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Minimal Residual Disease
16 Minimal Residual Disease Market Key Opinion Leaders Reviews
18 Minimal Residual Disease Market Drivers
19 Minimal Residual Disease Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Minimal Residual Disease Epidemiology 2032
DelveInsight’s “Minimal Residual Disease – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Minimal Residual Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Minimal Residual Disease Pipeline 2024
“Minimal Residual Disease Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Minimal Residual Disease market. A detailed picture of the Minimal Residual Disease pipeline landscape is provided, which includes the disease overview and Minimal Residual Disease treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
